Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Key findings: CagriSema achieved up to 23% weight loss at 84 weeks Tirzepatide showed numerical superiority (~25.5%) The trial did not meet non-inferiority vs tirzepatide Clinical interpretation: Despite not meeting the primary endpoint, an important signal emerges: targeting multiple biological pathways remains a compelling strategy Why this matters: Reinforces obesity as a complex neuroendocrine disease Supports the concept that multi-hormonal approaches may better impact the defended weight set point Moves the field closer to precision, mechanism-based therapies Safety: Consistent with the GLP-1 class Mainly gastrointestinal adverse events, generally mild to moderate and transient Whats next: Ongoing development with higher-dose CagriSema Expansion of the REDEFINE program FDA decision expected by late 2026 Take-home message: The future of obesity treatment lies not in a single pathway, but in strategically combining mechanisms to sustainably shift weight biology
EBioMedicine 25 , 154164 (2017)
If a package arrives warm, contact Simple Peptide immediately to discuss replacement options before using the product in any research protocol
Sambri I, Massa F, Gullo F, Meneghini S, Cassina L, Carraro M, et al
Cells 13, 1945
